Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Rezlidhia (olutasidenib)
i
Other names:
FT-2102, FT 2102
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(9)
News
Trials
Company:
Kissei, Novo Nordisk, Rigel
Drug class:
IDH1 inhibitor
Related drugs:
‹
ivosidenib (34)
vorasidenib (6)
GSK321 (3)
AGI-5198 (2)
BAY1436032 (1)
LY3410738 (1)
NMS-173 (1)
HMPL-306 (0)
IDH1 inhibitor (0)
IDH305 (0)
KY100001 (0)
DS-1001 (0)
ivosidenib (34)
vorasidenib (6)
GSK321 (3)
AGI-5198 (2)
BAY1436032 (1)
LY3410738 (1)
NMS-173 (1)
HMPL-306 (0)
IDH1 inhibitor (0)
IDH305 (0)
KY100001 (0)
DS-1001 (0)
›
Associations
(9)
News
Trials
VERI cancer hierarchy
Reset Filters
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
olutasidenib
Sensitive: A1 - Approval
olutasidenib
Sensitive
:
A1
olutasidenib
Sensitive: A1 - Approval
olutasidenib
Sensitive
:
A1
IDH1 R132
Acute Myelogenous Leukemia
IDH1 R132
Acute Myelogenous Leukemia
olutasidenib
Sensitive: C2 – Inclusion Criteria
olutasidenib
Sensitive
:
C2
olutasidenib
Sensitive: C2 – Inclusion Criteria
olutasidenib
Sensitive
:
C2
IDH1 mutation
Myelodysplastic Syndrome
IDH1 mutation
Myelodysplastic Syndrome
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
IDH1 R132G
Acute Myelogenous Leukemia
IDH1 R132G
Acute Myelogenous Leukemia
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
IDH1 R132C
Acute Myelogenous Leukemia
IDH1 R132C
Acute Myelogenous Leukemia
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
IDH1 R132L
Acute Myelogenous Leukemia
IDH1 R132L
Acute Myelogenous Leukemia
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
IDH1 R132S
Acute Myelogenous Leukemia
IDH1 R132S
Acute Myelogenous Leukemia
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
olutasidenib
Sensitive: C3 – Early Trials
olutasidenib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login